BlossomHill Presents Phase 1/2 Data for BH-30643 in NSCLC
Show Chart?
Load external content from TradingView!
*You can change or withdraw your consent at any time in the footer under Cookies.
BlossomHill Therapeutics Presents Updated Phase 1/2 Data for BH-30643 in EGFR-Mutant NSCLC
SAN DIEGO, September 15, 2026 -- BlossomHill Therapeutics, Inc. (Nasdaq: BLSM), a clinical-stage biopharmaceutical company, announced updated clinical data from the ongoing Phase 1/2 SOLARA trial of BH-30643 in non-small cell lung cancer (NSCLC) patients with secondary epidermal growth factor receptor (EGFR) resistance mutations, such as EGFR C797S. The data were presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer in Seoul, South Korea.
BH-30643 is an investigational, orally bioavailable, non-covalent, macrocyclic, brain active, mutant-selective OMNI-EGFR inhibitor. In patients with EGFR C797S-positive resistance to prior EGFR inhibitors, with or without concurrent T790M, the treatment demonstrated significant anti-tumor activity and a favorable safety profile.
Key Highlights
- In 40 patients with EGFR C797S-positive resistance, BH-30643 demonstrated an objective response rate of 45% and a disease control rate of 88%.
- At the time of efficacy follow-up, 63% of patients remained on treatment with a median follow-up of 6.9 months.
- Patients had received a median of two prior lines of therapy, including prior osimertinib, chemotherapy, antibody-drug conjugates, and a history of brain metastases.
- Treatment-related dose reductions and discontinuations were low at 9% and 3%, respectively, among patients treated at expansion doses.
